Similar articles

• Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.

  Roukos DH, Tzakos A, Zografos G. Roukos DH, et al. Expert Rev Anticancer Ther. 2009 Oct;9(10):1413-6. doi: 10.1586/era.09.116. Expert Rev Anticancer Ther. 2009. PMID: 19828000 No abstract available.
• Vascular endothelial growth factor as a target for antiangiogenic therapy.

  Gordon MS. Gordon MS. J Clin Oncol. 2000 Nov 1;18(21 Suppl):45S-6S. J Clin Oncol. 2000. PMID: 11060326 No abstract available.
• Combining radiotherapy and angiogenesis inhibitors: clinical trial design.

  Citrin D, Ménard C, Camphausen K. Citrin D, et al. Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):15-25. doi: 10.1016/j.ijrobp.2005.03.065. Int J Radiat Oncol Biol Phys. 2006. PMID: 16377411
• Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment.

  Gagne P, Akalu A, Brooks PC. Gagne P, et al. Expert Rev Anticancer Ther. 2004 Feb;4(1):129-40. doi: 10.1586/14737140.4.1.129. Expert Rev Anticancer Ther. 2004. PMID: 14748663 Review.
• Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.

  Glade Bender J, Cooney EM, Kandel JJ, Yamashiro DJ. Glade Bender J, et al. Drug Resist Updat. 2004 Aug-Oct;7(4-5):289-300. doi: 10.1016/j.drup.2004.09.001. Drug Resist Updat. 2004. PMID: 15533766 Review.